目的 探討采取消炎利膽膠囊聯(lián)合頭孢唑林鈉治療慢性膽囊炎患者的臨床效果。方法 選取子長縣人民醫(yī)院2016年3月-2017年3月收治的慢性膽囊炎患者125例，隨機(jī)分成對照組（62例）和治療組（63例）。對照組患者靜脈滴注注射用頭孢唑林鈉，1.0 g加入250 mL生理鹽水，2次/d，連續(xù)治療14 d。治療組患者在對照組的基礎(chǔ)上口服消炎利膽膠囊，3粒/次，3次/d，連續(xù)服用30 d。觀察兩組患者臨床療效，比較治療前后兩組患者主要臨床癥狀積分、肝膽功能生化指標(biāo)、炎性指標(biāo)和不良反應(yīng)情況。結(jié)果 治療后，對照組臨床總有效率為79.03%，顯著低于治療組的95.24%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者主要臨床癥狀積分顯著降低（P<0.05）；且治療組患者各癥狀積分比對照組降低的更明顯（P<0.05）。治療后，兩組丙氨酸氨基轉(zhuǎn)移酶（ALT）、門冬氨酸轉(zhuǎn)氨酶（AST）和總膽紅素（TBIL）均明顯降低（P<0.05）；且治療組肝膽功能生化指標(biāo)降低后水平明顯優(yōu)于對照組（P<0.05）。治療后，兩組患者超敏C反應(yīng)蛋白（hs-CRP）、IL-6和腫瘤壞死因子-α（TNF-α）均較治療前明顯降低（P<0.05）；且治療組各炎性指標(biāo)比對照組降低的更明顯（P<0.05）。治療期間，治療組患者不良反應(yīng)發(fā)生率明顯低于對照組患者，兩組患者比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 消炎利膽膠囊聯(lián)合頭孢唑林鈉治療慢性膽囊炎療效顯著，可有效改善患者的肝膽功能與體內(nèi)炎性反應(yīng)，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical effect of Xiaoyan Lidan Capsules combined with cefazolin sodium in treatment of chronic cholecystitis. Methods Patients (125 cases) with chronic cholecystitis in Zichang People's Hospital from March 2016 to March 2017 were randomly divided into control (62 cases) and treatment (63 cases) groups. Patients in the control group were iv administered with Cefazolin Sodium for injection, 1 g added into normal saline 250 mL, twice daily, and they were treated for 14 d. Patients in the treatment group were po administered with Xiaoyan Lidan Capsules on the basis of the control group, 3 grains/time, three times daily, and they were treated for 30 d. After treatment, the clinical efficacy was evaluated, and the main clinical symptom scores, hepatobiliary biochemical indicators, inflammatory indicators and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 79.03%, which were significantly lower than 95.24% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the main clinical symptom scores in two groups was significantly decreased (P<0.05). And these scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the ALT, AST and TBIL levels in two groups were significantly decreased (P<0.05). And the hepatobiliary biochemical indicators in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the Hs-CRP, IL-6 and TNF-α levels in two groups were significantly decreased (P<0.05). And the inflammatory indicators levels in the treatment group were significantly lower than those in the control group (P<0.05). During the treatment, the incidence of adverse reactions in the treatment was significantly lower than that in the control group, with significant difference between two groups (P<0.05). Conclusion Xiaoyan Lidan Capsules combined with cefazolin sodium has obvious curative effect in treatment of chronic cholecystitis, can improve the liver function and inflammatory reaction, which has a certain clinical application value.